Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

References

• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 2003;40:59–71.
   PubMed Web of Science ®Google Scholar
• McGlave PB, De Fabritiis P, Deisseroth A, et al Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994;343:1486–1488.
   PubMed Web of Science ®Google Scholar
• Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia. Br J Haematol 1994;86:76–81.
   PubMed Web of Science ®Google Scholar
• Deisseroth AB, Zu Z, Claxton D, et al Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068–3076.
   PubMed Web of Science ®Google Scholar
• Barnett MJ, Eaves CJ, Phillips GL, et al Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994;84:724–732.
   PubMed Web of Science ®Google Scholar
• Carella AM, Lerma E, Corsetti MT, et al Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999;93:1534–1539.
   PubMed Web of Science ®Google Scholar
• Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992;79:1003–1010.
   PubMed Web of Science ®Google Scholar
• Kreuzer KA, Kluhs C, Baskaynak G, Movassaghi K, Dorken B, le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004;124:195–199.
   PubMed Web of Science ®Google Scholar
• Gordon MK, Sher D, Karrison T, et al Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 2008;49:531–537.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774–1780.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27: 6041–6051.
   PubMed Web of Science ®Google Scholar
• Selvaggi KJ, Wilson JW, Mills LE, et al Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood 1994;83:1698–1705.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, O'Brien S, et al Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425–3432.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913–923.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D, et al Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58–60.
   PubMed Web of Science ®Google Scholar
• Olavarria E. Autologous stem cell transplantation in chronic myeloid leukemia. Semin Hematol 2007;44:252–258.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Schwendener A, et al The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2010 Mar29. [Epub ahead of print].
   Google Scholar
• Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439–449.
   PubMed Web of Science ®Google Scholar
• Olavarria E, Parker S, Craddock C, et al Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. Haematologica 2000;85:647–652.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Michallet M, Philip I, et al Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997;99:678–684.
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Carreras E, Cervantes F, et al Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica 2002;87:17–22.
   PubMed Web of Science ®Google Scholar
• Michallet M, Thiebaut A, Philip I, et al Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha. Leukemia 2000;14:2064–2069.
   PubMed Web of Science ®Google Scholar
• Russo D, Martinelli G, Montefusco V, Amabile M, Rosti G, Marin L. Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy. Haematologica 1999;84:953–935.
   PubMed Web of Science ®Google Scholar
• Reiffers J, Taylor K, Gluckman E, et al Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol 1998;102: 639–646.
   PubMed Web of Science ®Google Scholar
• Hui CH, Goh KY, White D, et al Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003;17:821–828.
   PubMed Web of Science ®Google Scholar
• Perseghin P, Gambacorti-Passerini C, Tornaghi L, et al Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion 2005;45:1214–1220.
   PubMed Web of Science ®Google Scholar
• Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003;123:479–483.
   PubMed Web of Science ®Google Scholar
• Vokurka S, Koza V, Lysak D, et al Successful peripheral blood stem cells collection in imatinib pretreated and nilotinib-treated chronic myeloid leukemia patient. J Oncol 2010;2010:460859.
   PubMedGoogle Scholar
• Hui CH, Hughes TP. Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench. Leuk Lymphoma 2006;47:1721–1723.
   PubMed Web of Science ®Google Scholar